Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | KDM5A | P29375 | 4/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.36 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678851 | 1.00 | SIGMAR1 (0.44) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL1678868 | 0.98 | SIGMAR1 (0.41) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL1678409 | 0.91 | — | — | |
| SCHEMBL8861067 | 0.90 | SIGMAR1 (0.58) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL8860836 | 0.90 | SIGMAR1 (0.58) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL8861016 | 0.88 | SIGMAR1 (0.55) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL5653604 | 0.83 | SIGMAR1 (0.44) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL5649211 | 0.81 | — | — | |
| SCHEMBL4871929 | 0.81 | SIGMAR1 (0.47) | SIGMAR1KDM5APHF8KDM2AKDM4C | |
| SCHEMBL3425766 | 0.78 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | SIGMAR1 4028/4885KDM5A 4777/4885PHF8 3699/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | SIGMAR1 706/4885KDM5A 2057/4885PHF8 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.